John Wiley & Sons Cancer Biomarkers Cover The past five years have witnessed an unprecedented acceleration in the search for disease biomarker.. Product #: 978-0-471-74516-7 Regular price: $154.21 $154.21 In Stock

Cancer Biomarkers

Analytical Techniques for Discovery

Hamdan, Mahmoud H.

Wiley-Interscience Series on Mass Spectrometry

Cover

1. Edition March 2007
408 Pages, Hardcover
Wiley & Sons Ltd

ISBN: 978-0-471-74516-7
John Wiley & Sons

Short Description

The past five years have witnessed an unprecedented acceleration in the search for disease biomarkers, the lion's share directed toward biomarkers associated with the various forms of cancer. Cancer Biomarkers: Technology and Discovery provides a comprehensive overview of the technologies involved in identifying cancer biomarkers, which is crucial for designing new ways to diagnose, treat, and one day, cure this deadly disease. The book provides the reader with insight into the most recent discoveries, technologies, and applications for biomarker research and discusses existing biomarkers, potential biomarkers, the various technological platforms, regulatory and ethical issues, and the emerging roles of protein networks, cell signaling, and tyrosine kinases.

Further versions

mobipdf

Tools, techniques, and progress in cancer biomarkers discovery

The completion of a number of gene sequencing projects, recent advances in genomic and proteomic technologies, and the availability of powerful bioinformatics tools have led to promising new avenues and approaches in the search for cancer biomarkers. This book provides a comprehensive overview of current methodologies and technologies. It discusses biomarker discovery as a whole, rather than focusing on one specific marker or cancer. With information on both existing and potential biomarkers, Cancer Biomarkers: Analytical Techniques for Discovery:
* Provides insights into the current technological platforms for biomarker discovery, including mass spectrometry combined with multidimensional chromatography, DIGE, and various chip technologies
* Includes a detailed discussion of protein networks and protein phosphorylation in cancer
* Details the use of imaging mass spectrometry, laser capture microdissection, serial analysis of gene expression, enzyme-linked immunosorbent assays, protein microarrays, antibody-based microarrays, and bioinformatics
* Covers the emerging role of surface-enhanced laser desorption ionization (SELDI) and various tagging and labeling strategies
* Discusses related regulatory and ethical issues

With a wealth of information that can be applied to a broad spectrum of biomarker research projects, this is a core reference for biomarker researchers, scientists working in proteomics and bioinformatics, pharmaceutical scientists, oncologists, biochemists, biologists, and chemists.

Preface.

Acknowledgments.

Introduction.

1 Overview.

1.1. Introduction.

1.2. Cancer Biomarkers.

1.3. Phases of Biomarkers Development.

1.4. New Approach to Biomarkers Discovery.

1.5. Initiatives Relevant to Biomarkers Discovery.

1.6. Concluding Remarks.

References.

2 Proteomic Platforms for Biomarkers Discovery.

2.1. Surface Enhanced Laser Desorption Ionization.

2.2. Bioinformatics in SELDI.

2.3. Some Representative SELDI Applications.

2.4. Two-dimensional Polyacrylamide Gel Electrophoresis.

2.5. Laser Capture Microdissection.

2.6. MS Analysis of Gel-separated Proteins.

2.7. Representative Applications of 2-DE for Biomarkers Discovery.

2.8. Protein Microarrays.

2.9. Multidimensional Liquid Chromatography Coupled to MS.

2.10. Chromatographic Separation.

2.11. Imaging Mass Spectrometry.

References.

3 Some Existing Cancer Biomarkers.

3.1. Introduction.

3.2. Historic Glimpse at PSA.

3.3. Prostate-specifi c Antigen.

3.4. PSA as a Screening Marker.

3.5. Improving the Specifi city of PSA.

3.6. Looking for Other Solutions.

3.7. Concluding Remarks.

3.8. Existing Biomarkers for Ovarian Cancer.

3.9. Osteopontin.

3.10. Combination of CA-125 with Other Potential Biomarkers.

3.11. Profi ling Proteins and Gene Expression in Ovarian Cancer.

3.12. General Observations.

References.

4 Potential Cancer Biomarkers.

4.1. Introduction.

4.2. Human Tissue Kallikreins.

4.3. Protein Family 14-3-3.

4.4. Heat Shock Proteins (HSPs).

4.5. Heat Shock Protein 27 (HSP27).

4.6. Heat Shock Protein 70 (HSP70).

4.7. General Remarks.

4.8. Calcium Binding Proteins.

4.9. DNA Methylation.

4.10. DNA Methylation in Cancer.

4.11. Inhibition of DNA Methylation.

4.12. Concluding Remarks.

References.

5 Protein Networks and Protein Phosphorylation in Cancer.

5.1. Introduction.

5.2. Protein Interaction Networks.

5.3. Computational Approaches.

5.4. Human Protein Intractome.

5.5. Relationship Between Gene Expression and Protein Interaction.

5.6. Gene Signatures in Cancer Prediction/Classifi cation.

5.7. Concluding Remarks.

5.8. Protein Phosphorylation.

5.9. Other Approaches.

5.10. The Phosphatidylinositol 3-Kinase-Akt Pathway (PI3K-Akt).

5.11. PIK3/Akt Alterations and Prognostic Biomarkers.

5.12. General Observations.

References.

6 Ethical Issues and Initiatives Relevant to Cancer Biomarkers.

6.1. Introduction.

6.2. Background.

6.3. Ethical Committees/Organizations.

6.4. Human Biobanks.

6.5. Large Population Screening.

6.6. Genetic Testing for Cancer Susceptibility.

6.7. Ethics in Phase I Oncology Trials.

6.8. Initiatives Relevant to Biomarkers Discovery.

6.9. Genomic Initiatives/Resources.

6.10. Achievements and Perspectives.

References.

Abbreviations.

Index.
MAHMOUD H. HAMDAN, PhD, FInstP, is the head of the Mass Spectrometry and Separation Technologies Laboratory at GlaxoSmithKline in Verona, Italy. He is a coauthor of Proteomics Today: Protein Assessment and Biomarkers Using Mass Spectrometry, 2D Electrophoresis, and Microarray Technology, also from Wiley.

M. H. Hamdan, GlaxoSmithKline, Italy